European Society for Medical Oncology (ESMO) Congress 2022

Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC

Roshini Claire Anthony, 20221215180001

The first-in-class KRAS^G12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRAS^G12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.

FRESCO-2: Fruquintinib improves OS in heavily pretreated mCRC

Elaine Soliven, 20221130000000

Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.

KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment

Christina Lau, 20221111055344

An extended 4.5-year follow-up of the phase III KEYNOTE-240 trial showed that pembrolizumab continued to provide clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), with a manageable safety profile, vs placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC).

Atezolizumab bests chemo in advanced NSCLC

Elvira Manzano, 20221109000000

First-line immunotherapy treatment with atezolizumab – a PD-L1 inhibitor – offers a survival advantage over single-agent chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for platinum doublets in the phase III IPSOS trial.

TIL therapy improves PFS in patients with advanced melanoma

Elaine Soliven, 20221109000000

Tumour-infiltrating lymphocyte therapy significantly improved progression-free survival (PFS) in patients with advanced melanoma compared with standard-of-care treatment with ipilimumab, according to the M14TIL trial presented at ESMO 2022.

COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC

Roshini Claire Anthony, 20221104180001

The combination of nivolumab, ipilimumab, and cabozantinib improved progression-free survival (PFS) in patients with previously untreated, advanced renal cell carcinoma (RCC) of intermediate or poor risk as per IMDC* criteria, results of the phase III COSMIC-313 trial showed.

Could a pembro + CRT combo improve outcomes in locally advanced head and neck SCC?

Roshini Claire Anthony, 20221030100001

Combining pembrolizumab with chemoradiation therapy (CRT) showed a trend toward improved event-free survival (EFS) compared with CRT alone in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), primary results of the phase III KEYNOTE-412 trial showed.

Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC

Audrey Abella, 20221028100000

In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.

Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment

Audrey Abella, 20221019100000

In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).

Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer

Audrey Abella, 20221012100000

In the second interim overall survival (OS) analysis of the phase III TROPiCS-02 study, sacituzumab govitecan (SG) – a first-in-class Trop-2*-directed antibody-drug conjugate approved for triple-negative metastatic breast cancer (mBC) with ≥2 prior therapies (≥1 in the metastatic setting) – conferred an OS benefit for pretreated HR+/HER2– mBC, compared with treatment of physician’s choice (TPC**).